X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-05-16 | DYN | Dyne Therapeutics, Inc. | Beskrovnaya Oxana | Chief Scientific Officer | S - Sale | $28.27 | -2,705 | 149,647 | -2% | -$76,469 | ||||||
2024-05-16 | DYN | Dyne Therapeutics, Inc. | Farwell Wildon | Chief Medical Officer | S - Sale | $28.27 | -2,381 | 148,179 | -2% | -$67,310 | ||||||
2024-05-16 | DYN | Dyne Therapeutics, Inc. | High Susanna Gatti | COO | S - Sale | $28.27 | -2,738 | 154,062 | -2% | -$77,402 | ||||||
2024-05-16 | DYN | Dyne Therapeutics, Inc. | Scalzo Richard William | SVP, Head of Finance, Admin. | S - Sale | $28.27 | -2,588 | 116,695 | -2% | -$73,162 | ||||||
2024-05-16 | DYN | Dyne Therapeutics, Inc. | McNeill Jonathan | Chief Business Officer | S - Sale | $28.27 | -2,774 | 136,634 | -2% | -$78,420 | ||||||
2024-05-17 | PEPG | Pepgen Inc. | Svenstrup Niels | SVP, Chem. Mfg, Controls | S - Sale | $13.41 | -10,000 | 0 | -100% | -$134,100 | ||||||
| D | 2024-05-15 | MCRB | Seres Therapeutics, Inc. | Von Moltke Lisa | See Remarks | S - Sale+OE | $0.94 | -939 | 19,017 | -5% | -$883 | |||||
| D | 2024-05-15 | MCRB | Seres Therapeutics, Inc. | Shaff Eric D. | CEO, Pres | S - Sale+OE | $0.94 | -2,435 | 140,698 | -2% | -$2,289 | |||||
| D | 2024-05-15 | MCRB | Seres Therapeutics, Inc. | Young Teresa L. | See Remarks | S - Sale+OE | $0.94 | -703 | 17,658 | -4% | -$661 | |||||
| D | 2024-05-15 | MCRB | Seres Therapeutics, Inc. | Henn Matthew R. | See Remarks | S - Sale+OE | $0.94 | -891 | 65,357 | -1% | -$838 | |||||
| D | 2024-05-15 | MCRB | Seres Therapeutics, Inc. | Ege David S. | See Remarks | S - Sale+OE | $0.94 | -1,090 | 75,734 | -1% | -$1,025 | |||||
| D | 2024-05-15 | MCRB | Seres Therapeutics, Inc. | Desrosier Thomas | GC, EVP | S - Sale+OE | $0.94 | -843 | 122,390 | -1% | -$792 | |||||
2024-05-09 | LGND | Ligand Pharmaceuticals Inc | Gray Nancy Ryan | Dir | S - Sale | $83.20 | -934 | 5,633 | -14% | -$77,713 | ||||||
| DM | 2024-05-15 | LGND | Ligand Pharmaceuticals Inc | Espinoza Octavio | CFO | S - Sale+OE | $86.26 | -13,293 | 23,379 | -36% | -$1,146,704 | |||||
2024-05-15 | VERU | Veru Inc. | Fisch Harry | Chief Corporate Officer | P - Purchase | $1.49 | +6,711 | 8,009,832 | 0% | +$9,999 | ||||||
| M | 2024-05-15 | VERU | Veru Inc. | Steiner Mitchell Shuster | Pres, CEO | S - Sale | $1.44 | -171,875 | 7,156,892 | -2% | -$246,929 | |||||
| D | 2024-05-17 | AVTE | Aerovate Therapeutics, Inc. | Gillies Hunter | CHIEF MEDICAL OFFICER | S - Sale+OE | $21.08 | -4,000 | 5,602 | -42% | -$84,332 | |||||
| D | 2024-05-16 | AVTE | Aerovate Therapeutics, Inc. | Noyes Timothy P | CEO | S - Sale+OE | $21.58 | -10,000 | 0 | -100% | -$215,755 | |||||
| D | 2024-05-16 | DAWN | Day One Biopharmaceuticals, Inc. | Bender Jeremy | CEO | S - Sale+OE | $16.08 | -7,873 | 1,698,452 | 0% | -$126,588 | |||||
| D | 2024-05-16 | DAWN | Day One Biopharmaceuticals, Inc. | Blackman Samuel C. | HEAD OF R, D | S - Sale+OE | $16.08 | -2,267 | 2,171,081 | 0% | -$36,450 | |||||
| D | 2024-05-16 | DAWN | Day One Biopharmaceuticals, Inc. | York Charles N II | COO, CFO, Secretary | S - Sale+OE | $16.08 | -2,675 | 224,868 | -1% | -$43,011 | |||||
| D | 2024-05-16 | DAWN | Day One Biopharmaceuticals, Inc. | Dubow Adam | GC | S - Sale+OE | $16.08 | -3,253 | 21,731 | -13% | -$52,304 | |||||
| M | 2024-05-15 | ANIP | Ani Pharmaceuticals Inc | Shanmugam Muthusamy | HEAD OF R, D, COO-NOVITIUM OPS | S - Sale | $64.37 | -37,145 | 819,127 | -4% | -$2,391,121 | |||||
2024-05-16 | ANIP | Ani Pharmaceuticals Inc | Tannenbaum Renee P | Dir | S - Sale | $63.87 | -2,000 | 18,211 | -10% | -$127,740 | ||||||
2024-05-17 | REGN | Regeneron Pharmaceuticals, Inc. | Schleifer Leonard S | Bd. Co-Chair, Pres, CEO | S - Sale | $979.23 | -22,830 | 695,346 | -3% | -$22,355,714 | ||||||
2024-05-17 | OPK | Opko Health, Inc. | Frost Phillip Md Et Al | CEO, COB, 10% | P - Purchase | $1.29 | +163,997 | 244,328,350 | 0% | +$211,195 | ||||||
| D | 2024-05-15 | NUVL | Nuvalent, Inc. | Conley Emily | Dir | S - Sale+OE | $69.09 | -5,000 | 8 | -100% | -$345,450 | |||||
2024-05-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Sachdev Amit | EVP Chief Patient, Ext Af Off | S - Sale | $430.93 | -32 | 62,772 | 0% | -$13,790 | ||||||
2024-05-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Arbuckle Stuart A | EVP, COO | S - Sale | $430.93 | -69 | 49,831 | 0% | -$29,734 | ||||||
2024-05-15 | VRTX | Vertex Pharmaceuticals Inc / Ma | Altshuler David | EVP, Chief Scientific Officer | S - Sale | $430.93 | -54 | 25,813 | 0% | -$23,270 | ||||||
| DM | 2024-05-15 | VERA | Vera Therapeutics, Inc. | Young Joseph R | SVP, Finance, Chief Acct Offcr | S - Sale+OE | $42.30 | -30,837 | 51,206 | -38% | -$1,304,435 | |||||
2024-05-17 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale | $25.09 | -4,642 | 106,134 | -4% | -$116,468 | ||||||
2024-05-17 | INSM | Insmed Inc | Adsett Roger | COO | S - Sale | $25.09 | -5,945 | 149,275 | -4% | -$149,160 | ||||||
2024-05-16 | REGN | Regeneron Pharmaceuticals, Inc. | Yancopoulos George | Bd. Co-Chair, Pres, CSO | S - Sale | $972.73 | -50,000 | 1,148,844 | -4% | -$48,636,545 | ||||||
| D | 2024-05-15 | BPMC | Blueprint Medicines Corp | Hurley Ariel | Principal Accounting Officer | S - Sale+OE | $106.96 | -5,856 | 14,913 | -28% | -$626,379 | |||||
| D | 2024-05-15 | GERN | Geron Corp | Lawlis V Bryan | Dir | S - Sale+OE | $3.75 | -35,000 | 0 | -100% | -$131,250 | |||||
2024-05-15 | BPMC | Blueprint Medicines Corp | Landsittel Michael | CFO | S - Sale | $106.95 | -3,850 | 71,617 | -5% | -$411,772 | ||||||
2024-05-15 | REGN | Regeneron Pharmaceuticals, Inc. | Yancopoulos George | Bd. Co-Chair, Pres, CSO | S - Sale | $975.88 | -50,000 | 1,198,844 | -4% | -$48,793,727 | ||||||
2024-05-17 | ZOM | Zomedica Corp. | Powers Johnny D | Dir | P - Purchase | $0.17 | +100,000 | 2,225,000 | +5% | +$17,450 | ||||||
2024-05-16 | ZOM | Zomedica Corp. | Powers Johnny D | Dir | P - Purchase | $0.18 | +25,000 | 2,125,000 | +1% | +$4,600 | ||||||
| M | 2024-05-15 | TEVA | Teva Pharmaceutical Industries Ltd | Weiss Amir | Chief Accounting Officer | S - Sale | $16.73 | -28,135 | 5,179 | -84% | -$470,794 | |||||
| D | 2024-05-14 | MDGL | Madrigal Pharmaceuticals, Inc. | Craves Fred B | Dir | S - Sale+OE | $212.88 | -22,489 | 489,685 | -4% | -$4,787,404 | |||||
| M | 2024-05-14 | SPRY | Ars Pharmaceuticals, Inc. | Tanimoto Sarina | Chief Medical Officer, 10% | S - Sale | $9.05 | -100,000 | 12,665,600 | -1% | -$905,441 | |||||
| M | 2024-05-14 | SPRY | Ars Pharmaceuticals, Inc. | Lowenthal Richard E | Pres, CEO, 10% | S - Sale | $9.05 | -100,000 | 14,307,793 | -1% | -$905,441 | |||||
| M | 2024-05-14 | AMLX | Amylyx Pharmaceuticals, Inc. | Quimi Daphne | Dir | P - Purchase | $1.89 | +5,000 | 5,000 | New | +$9,436 | |||||
2024-05-15 | AMLX | Amylyx Pharmaceuticals, Inc. | Mazzariello Gina | GC | S - Sale | $1.88 | -10,455 | 151,477 | -6% | -$19,654 | ||||||
| D | 2024-05-14 | ELVN | Enliven Therapeutics, Inc. | Patel Anish | COO | S - Sale+OE | $25.00 | -1,107 | 394,027 | 0% | -$27,675 | |||||
| D | 2024-05-14 | COLL | Collegium Pharmaceutical, Inc | Bohlin Garen G | Dir | S - Sale+OE | $32.30 | -28,985 | 52,468 | -36% | -$936,311 | |||||
2024-05-03 | TSVT | 2Seventy Bio, Inc. | Snow Jessica | See Remarks | S - Sale | $4.91 | -15 | 56,271 | 0% | -$74 | ||||||
| D | 2024-05-14 | RNA | Avidity Biosciences, Inc. | Maclean Michael F | CFO | S - Sale+OE | $28.28 | -75,000 | 44,093 | -63% | -$2,121,045 | |||||
| DM | 2024-05-14 | IDYA | Ideaya Biosciences, Inc. | Hata Yujiro S | Pres, CEO | S - Sale+OE | $42.27 | -175,000 | 677,887 | -21% | -$7,397,291 | |||||
2024-05-15 | CYRX | Cryoport, Inc. | Berman Richard J | Dir | S - Sale | $13.41 | -8,105 | 100,000 | -7% | -$108,693 | ||||||
2024-05-14 | ANIP | Ani Pharmaceuticals Inc | Lalwani Nikhil | Pres, CEO | S - Sale | $66.10 | -16,669 | 377,505 | -4% | -$1,101,821 | ||||||
2024-05-14 | ZLAB | Zai Lab Ltd | Edmondson Frazor Titus III | GC | S - Sale | $21.33 | -10,000 | 16,408 | -38% | -$213,346 | ||||||
2024-05-14 | TRDA | Entrada Therapeutics, Inc. | Kim Peter S | Dir | P - Purchase | $14.59 | +25,000 | 92,412 | +37% | +$364,673 | ||||||
| D | 2024-05-15 | UTHR | United Therapeutics Corp | Causey Christopher | Dir | S - Sale+OE | $272.90 | -2,000 | 4,185 | -32% | -$545,800 | |||||
| D | 2024-05-15 | UTHR | United Therapeutics Corp | Edgemond James | CFO, TREASURER | S - Sale+OE | $272.69 | -40,160 | 1,578 | -96% | -$10,951,230 | |||||
| DM | 2024-05-14 | UTHR | United Therapeutics Corp | Rothblatt Martine A | CHAIRPERSON, CEO | S - Sale+OE | $270.35 | -7,200 | 130 | -98% | -$1,946,522 | |||||
2024-05-15 | ETST | Earth Science Tech, Inc. | Tabraue Mario Guillermo | COO | P - Purchase | $0.15 | +10,000 | 12,291,023 | 0% | +$1,500 | ||||||
2024-05-14 | RPHM | Reneo Pharmaceuticals, Inc. | Leonard Braden Michael | 10% | P - Purchase | $1.54 | +414,281 | 3,692,963 | +13% | +$639,578 | ||||||
2024-05-15 | BSPK | Bespoke Extracts, Inc. | Feinsod Michael | CEO, 10% | P - Purchase | $0.15 | +3,000 | 2,136,112 | 0% | +$450 | ||||||
| D | 2024-05-13 | CORT | Corcept Therapeutics Inc | Maduck Sean | See Remarks | S - Sale+OE | $28.00 | -50,000 | 105,222 | -32% | -$1,400,000 | |||||
| M | 2024-05-13 | LGND | Ligand Pharmaceuticals Inc | Korenberg Matthew E | Pres, COO | S - Sale | $84.99 | -17,598 | 86,263 | -17% | -$1,495,740 | |||||
2024-05-14 | CYRX | Cryoport, Inc. | Zecchini Edward J | Chief Digital, Tech Officer | S - Sale | $13.37 | -3,443 | 60,051 | -5% | -$46,042 | ||||||
2024-05-14 | ARDX | Ardelyx, Inc. | Raab Michael | Pres, CEO | S - Sale | $7.99 | -3,000 | 1,333,297 | 0% | -$23,970 | ||||||
| DM | 2024-05-14 | REGN | Regeneron Pharmaceuticals, Inc. | Schleifer Leonard S | Bd. Co-Chair, Pres, CEO | S - Sale+OE | $979.58 | -35,941 | 718,176 | -5% | -$35,207,110 | |||||
| M | 2024-05-13 | GNLX | Genelux Corp | Szalay Aladar | 10% | S - Sale | $3.63 | -35,966 | 3,953,581 | -1% | -$130,377 | |||||
2024-05-14 | VERV | Verve Therapeutics, Inc. | Ashe Andrew D. | See Remarks | P - Purchase | $6.26 | +76,000 | 342,509 | +29% | +$475,760 | ||||||
2024-05-15 | CLSD | Clearside Biomedical, Inc. | Yerxa Benjamin R | Dir | P - Purchase | $1.31 | +7,813 | 17,957 | +77% | +$10,235 | ||||||
| M | 2024-05-13 | EOLS | Evolus, Inc. | Gill David N | Dir | S - Sale | $12.64 | -10,361 | 33,964 | -23% | -$131,010 | |||||
2024-05-13 | EOLS | Evolus, Inc. | Malik Vikram | Dir | S - Sale | $12.93 | -28,000 | 254,014 | -10% | -$362,012 | ||||||
2024-05-13 | NUVL | Nuvalent, Inc. | Shair Matthew | Dir | S - Sale | $65.84 | -37,500 | 1,661,220 | -2% | -$2,468,866 | ||||||
2024-05-14 | LIPO | Lipella Pharmaceuticals Inc. | Kaufman Jonathan H | See remarks below., 10% | P - Purchase | $0.76 | +10,000 | 898,849 | +1% | +$7,590 | ||||||
| D | 2024-05-14 | INSM | Insmed Inc | Wise John Drayton | Chief Commercial Officer | S - Sale+OE | $25.47 | -5,088 | 123,259 | -4% | -$129,591 | |||||
| D | 2024-05-14 | INSM | Insmed Inc | Smith Michael Alexander | GC | S - Sale+OE | $25.40 | -5,093 | 94,579 | -5% | -$129,362 | |||||
| D | 2024-05-14 | INSM | Insmed Inc | Schaeffer Orlov S Nicole | Chief People Strategy Officer | S - Sale+OE | $25.53 | -6,508 | 108,760 | -6% | -$166,149 | |||||
| D | 2024-05-14 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $25.52 | -22,198 | 668,549 | -3% | -$566,493 | |||||
| D | 2024-05-14 | INSM | Insmed Inc | Flammer Martina M.D. | Chief Medical Officer | S - Sale+OE | $25.47 | -10,640 | 110,776 | -9% | -$271,001 | |||||
| D | 2024-05-14 | INSM | Insmed Inc | Bonstein Sara | CFO | S - Sale+OE | $25.32 | -11,088 | 117,481 | -9% | -$280,748 | |||||
| D | 2024-05-14 | INSM | Insmed Inc | Adsett Roger | COO | S - Sale+OE | $25.50 | -7,857 | 155,220 | -5% | -$200,354 | |||||
2024-05-14 | ZOM | Zomedica Corp. | Powers Johnny D | Dir | P - Purchase | $0.14 | +50,000 | 2,100,000 | +2% | +$6,981 | ||||||
| D | 2024-05-14 | UTHR | United Therapeutics Corp | Patusky Christopher | Dir | S - Sale+OE | $264.35 | -1,310 | 1,100 | -54% | -$346,299 | |||||
2024-05-13 | ALXO | Alx Oncology Holdings Inc | Randolph Sophia | Chief Medical Officer | S - Sale | $15.94 | -12,000 | 330,349 | -4% | -$191,339 | ||||||
2024-05-13 | GTHX | G1 Therapeutics, Inc. | Umstead John W. V | CFO | S - Sale | $4.79 | -8,151 | 153,245 | -5% | -$39,034 | ||||||
2024-05-13 | GTHX | G1 Therapeutics, Inc. | Murdock Terry L | COO | S - Sale | $4.79 | -8,151 | 95,487 | -8% | -$39,034 | ||||||
2024-05-13 | GTHX | G1 Therapeutics, Inc. | Malik Rajesh | Chief Medical Officer | S - Sale | $4.79 | -8,151 | 161,787 | -5% | -$39,034 | ||||||
2024-05-13 | GTHX | G1 Therapeutics, Inc. | Avagliano Mark | Chief Business Officer | S - Sale | $4.79 | -8,151 | 209,683 | -4% | -$39,034 | ||||||
2024-05-13 | GTHX | G1 Therapeutics, Inc. | Bailey John E. (Jack) Jr. | Pres, CEO | S - Sale | $4.79 | -37,258 | 452,336 | -8% | -$178,421 | ||||||
2024-05-13 | ZLAB | Zai Lab Ltd | Smiley Joshua L | See Remarks | P - Purchase | $21.40 | +3,000 | 31,684 | +10% | +$64,200 | ||||||
2024-05-14 | NVCT | Nuvectis Pharma, Inc. | Bentsur Ron | COB, CEO, 10% | P - Purchase | $6.74 | +1,940 | 3,246,424 | 0% | +$13,076 | ||||||
2024-05-13 | TEVA | Teva Pharmaceutical Industries Ltd | Conway Vikki L | See "Remarks" | S - Sale | $16.74 | -15,219 | 0 | -100% | -$254,807 | ||||||
2024-05-13 | BHVN | Biohaven Ltd. | Bailey Gregory | Dir | P - Purchase | $34.19 | +15,000 | 1,615,071 | +1% | +$512,877 | ||||||
2024-05-14 | ETST | Earth Science Tech, Inc. | Sanchez Yovan Arturo | Dir | P - Purchase | $0.14 | +150,000 | 910,500 | +20% | +$20,250 | ||||||
2024-05-14 | IMMX | Immix Biopharma, Inc. | Morris Gabriel S | CFO | P - Purchase | $2.23 | +4,500 | 332,519 | +1% | +$10,042 | ||||||
2024-05-14 | IMMX | Immix Biopharma, Inc. | Rachman Ilya M | CEO, COB | P - Purchase | $2.25 | +4,300 | 912,000 | 0% | +$9,660 | ||||||
2024-05-10 | IOBT | Io Biotech, Inc. | Novo Holdings A/S | 10% | S - Sale | $1.22 | -658,809 | 4,429,449 | -13% | -$802,495 | ||||||
2024-05-13 | MNKD | Mannkind Corp | Binder Steven B. | EVP Special Projects | S - Sale | $4.31 | -3,618 | 845,967 | 0% | -$15,594 | ||||||
2024-05-13 | MNKD | Mannkind Corp | Thomson David | EVP Genl Counsel, Secretary | S - Sale | $4.31 | -3,047 | 783,446 | 0% | -$13,133 | ||||||
2024-05-10 | EOLS | Evolus, Inc. | Moatazedi David | See Remarks | S - Sale | $12.72 | -16,051 | 673,563 | -2% | -$204,127 | ||||||
2024-05-10 | EOLS | Evolus, Inc. | Avelar Rui | See Remarks | S - Sale | $12.72 | -3,441 | 368,847 | -1% | -$43,761 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |